Core Viewpoint - The announcement from Zhongguancun indicates that its subsidiary, Shandong Huasu Pharmaceutical Co., has received approval from the National Medical Products Administration for the marketing application of the raw material drug Succinic Acid Metoprolol [2] Group 1 - Zhongguancun will disclose the consistency evaluation application for Naloxone Injection and the marketing application for Succinic Acid Metoprolol raw material drug by March 2024 [2] - Shandong Huasu's Succinic Acid Metoprolol raw material drug has passed the technical review by the National Medical Products Administration's Drug Evaluation Center [2] - The company has received the "Approval Notice for Chemical Raw Material Drug Marketing Application" issued by the National Medical Products Administration [2]
中关村:关于下属公司山东华素琥珀酸美托洛尔原料药获批上市的公告